• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cholestasis - Pipeline Review, H2 2012 Product Image

Cholestasis - Pipeline Review, H2 2012

  • ID: 2335348
  • November 2012
  • 34 pages
  • Global Markets Direct

Cholestasis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cholestasis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cholestasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cholestasis. Cholestasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cholestasis.
- A review of the Cholestasis products under development by companies and universities/research institutes based on information derived from READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Cholestasis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cholestasis 7
Cholestasis Therapeutics under Development by Companies 9
Cholestasis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Cholestasis Therapeutics – Products under Development by Companies 15
Cholestasis Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Cholestasis Therapeutics Development 17
AlbireoPharma 17
Cholestasis – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
omega-3 enriched intravenous fat emulsion - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
omegaven - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
omega-3 fatty acid - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
omegaven - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ursodiol - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ursodiol - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
A-4250 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Cholestasis Therapeutics - Dormant Products 31
Cholestasis – Product Development Milestones 32
Featured News & Press Releases 32
Jul 24, 2012: Albireo Receives Positive Opinion From EMA For Orphan Drug Designation For A4250 For Severe Liver Diseases 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables
Number of Products Under Development for Cholestasis, H2 2012 7
Products under Development for Cholestasis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
AlbireoPharma, H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Cholestasis Therapeutics – Dormant Products 31

List of Figures
Number of Products under Development for Cholestasis, H2 2012 7
Products under Development for Cholestasis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos